韩国LG生命科学 LG Life Sciences Ltd
LG集团所属的LG生命科学株式会社是韩国大型综合性制药公司，公司将新药研发作为公司发展的关键战略，并已经成功研发出世界水平的几种新药。LG生命科学秉承LG集团的经营理念，“为顾客创造价值”和“尊重人格的经营”。
北京乐金科技有限公司是LG集团旗下LG生命科学在中国的全资子公司。其前身是LG生命科学于2004年在北京设立的代表处。经过几年的探索和发展，根据总部的发展战略部署，2011年1月1日北京代表处成立了法人公司，进行医药产品的引进和市场拓展等业务。产品涵盖药品、医疗器械、医学美容、疫苗、诊断试剂和保健六大类。目前已在中国上市的产品有基因工程产品尤得盼®（Eutropin®，重组人生长激素）、阿司伯根®（重组人促红细胞生成素）、吉速星®（Factive®，吉米沙星原料药和片剂）、眼科手术耗材Hyal2000®（医用透明质酸钠凝胶）、纯天然护肤品安特柔系列（ATOverol®）和HCA&CLA抗衰老系列产品。正在注册中的有长效生长激素、注射美容类玻尿酸系列产品。

LG生命科学将继续致力于把世界一流的医药产品和技术引进到中国，服务于中国人民的健康。

        
 In the process, corporate value is being raised as we strive to attain our goal of being a top-tier pharmaceutical maker in the global market.

Our involvement in pharmaceuticals dates back to 1981, when we
began genetic engineering research as a division of LG Chemical. Since
then, we have focused on the development of synthetic and bioengineered drugs, and we have enjoyed noteworthy success. For example, our quinolone antibiotic FACTIVE® became the first-ever new drug developed in Korea to receive FDA approval in 2003. It is now available in the US market and sales are growing steadily.

The life sciences industry is committed to promoting human health and longevity. This business also
represents unlimited possibilities and potential for growth.

LG Life Sciences is contributing to the improvement of people health and life quality and is firmly
established as the Korean leader of this strategically important industry. In the future, all LG Life
Sciences employees will continue to strive for global prominence while operating as a highly ethical
corporation that has the public trust.